Clinical Trial Update: A Study of Renal Autologous Cell Therapy (REACT) in Type 2 Diabetics With Chronic Kidney Disease [Phase 2]

View source ↗

Summary

Prokidney's Renal Autologous Cell Therapy (REACT) Phase 2 trial in patients with type 2 diabetes mellitus and chronic kidney disease has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease
• Type 2 Diabetes Mellitus

Drugs mentioned

• Renal Autologous Cell Therapy (REACT)

Snippet

Sponsor: Prokidney | Conditions: Type 2 Diabetes Mellitus, Chronic Kidney Disease | Phase 2 | Status: COMPLETED